Division of Infectious Diseases and Global Health, University of California, San Diego, 4510 Executive Drive, Suite P7, La Jolla, San Diego, CA, 92121, USA.
Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, La Jolla, CA, USA.
Infection. 2019 Aug;47(4):665-668. doi: 10.1007/s15010-019-01319-0. Epub 2019 May 17.
We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.
The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later.
Given the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy.
我们描述了噬菌体疗法在一名 26 岁囊性纤维化(CF)患者中的应用,该患者正在等待肺移植。
患者发生多重耐药(MDR)铜绿假单胞菌肺炎、持续性呼吸衰竭和黏菌素诱导的肾衰竭。我们描述了在该患者中使用静脉内噬菌体疗法(BT)联合全身抗生素的情况,未发生不良反应,且该方法成功控制了感染。在 BT 结束后 100 天内,她没有出现假单胞菌肺炎和 CF 恶化的复发,并在 9 个月后成功进行了双侧肺移植。
鉴于 CF 患者中对 MDR 铜绿假单胞菌感染的担忧,BT 可能为传统抗生素治疗提供一种可行的抗感染辅助治疗方法。